News · 26 weeks75+100%
2025-12-142026-06-07
Mix4690d
- Insider28(61%)
- SEC Filings9(20%)
- Market7(15%)
- Other1(2%)
- Analyst1(2%)
Latest news
25 items- INSIDERDirector Richards Timothy T. sold $65,901 worth of shares (5,415 units at $12.17), decreasing direct ownership by 6% to 87,198 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- NEWSClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global FootprintAnnouncement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototy
- INSIDERSEC Form 4 filed by Director Johnson B Kristine4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Liau Linda M.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Fallon Lynnette C4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Fletcher R John4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Klein Matthew B. sold $185,440 worth of shares (16,000 units at $11.59), decreasing direct ownership by 25% to 46,935 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Richards Timothy T.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Fallon Lynnette C converted options into 12,417 shares and sold $56,714 worth of shares (5,091 units at $11.14) as part of a pre-agreed trading plan, increasing direct ownership by 18% to 48,227 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Klein Matthew B. converted options into 12,417 shares, increasing direct ownership by 25% to 62,935 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Richards Timothy T. converted options into 12,417 shares, increasing direct ownership by 15% to 92,613 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Fletcher R John converted options into 12,417 shares, increasing direct ownership by 11% to 130,349 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Johnson B Kristine converted options into 12,417 shares, increasing direct ownership by 21% to 71,116 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- SECClearPoint Neuro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)
- INSIDERDirector Liau Linda M. converted options into 12,417 shares, increasing direct ownership by 24% to 64,801 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Girin Pascal E R converted options into 12,417 shares, increasing direct ownership by 13% to 110,623 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- SECSEC Form S-8 filed by ClearPoint Neuro Inc.S-8 - ClearPoint Neuro, Inc. (0001285550) (Filer)
- SECSEC Form 144 filed by ClearPoint Neuro Inc.144 - ClearPoint Neuro, Inc. (0001285550) (Subject)
- SECSEC Form 10-Q filed by ClearPoint Neuro Inc.10-Q - ClearPoint Neuro, Inc. (0001285550) (Filer)
- SECClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)
- NEWSClearPoint Neuro Reports First Quarter 2026 ResultsRecord Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026.First Quarter 2026 HighlightsReported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025;The activated installed base across all ClearPoint technology including IRRAflow sy
- NEWSClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global FootprintSOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.The Velocity Alpha MR High Speed Surgical Drill System is manufactured by German-based surgical equipment leader Adeor Medical AG. It is a versatile pneumatic drill system designed to streamline ClearPoint procedures and improve case efficiency in both MR and operating room environments. The drill is purpose-built to
- ANALYSTStifel resumed coverage on ClearPoint Neuro with a new price targetStifel resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $16.00
- NEWSClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 first quarter on Wednesday, May 13th, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 first quarter results on Wednesday, May 13th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (
- SECSEC Form DEFA14A filed by ClearPoint Neuro Inc.DEFA14A - ClearPoint Neuro, Inc. (0001285550) (Filer)
CLPT FAQ
6 questionsWhat does ClearPoint Neuro Inc. do?
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally...Where does CLPT stock trade?
ClearPoint Neuro Inc. (CLPT) is listed on NASDAQ.What sector and industry is CLPT in?
ClearPoint Neuro Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about CLPT?
ClearPoint Neuro Inc. has had 5 recent analyst actions on file. The most recent action was from Stifel: Buy with a $1600.00 price target on 2026-05-08. Recent price targets range from $800.00 to $1600.00.What companies are similar to CLPT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare CLPT side-by-side with any of them on Quantisnow.How can I track CLPT on Quantisnow?
Quantisnow aggregates ClearPoint Neuro Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLPT to receive live email and push alerts on every new disclosure.